Prophylactic Thyroidectomy in RET Carriers at Risk for Hereditary Medullary Thyroid Cancer

Thyroid ◽  
2009 ◽  
Vol 19 (6) ◽  
pp. 551-554 ◽  
Author(s):  
Andreas Machens ◽  
Henning Dralle
Keyword(s):  
At Risk ◽  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Prophylactic Thyroidectomy ◽  
Medullary Thyroid ◽  
Hereditary Medullary Thyroid Cancer

scholarly journals Utility of serum thyroglobulin measurements after prophylactic thyroidectomy in patients with hereditary medullary thyroid cancer

Surgery ◽  
2014 ◽  
Vol 156 (2) ◽  
pp. 394-398
Author(s):  
Carolyn D. Seib ◽  
Avital Harari ◽  
Felix A. Conte ◽  
Quan-Yang Duh ◽  
Orlo H. Clark ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Prophylactic Thyroidectomy ◽  
Serum Thyroglobulin ◽  
Medullary Thyroid ◽  
Hereditary Medullary Thyroid Cancer

scholarly journals Indication and Timing of Thyroid Surgery for Patients with Hereditary Medullary Thyroid Cancer Syndromes

2006 ◽  
Vol 4 (2) ◽  
pp. 139-147 ◽  
Author(s):  
Jennifer B. Ogilvie ◽  
Electron Kebebew
Keyword(s):  
Thyroid Cancer ◽  
Multiple Endocrine Neoplasia ◽  
Medullary Thyroid Cancer ◽  
Autosomal Dominant ◽  
Point Mutations ◽  
Prophylactic Thyroidectomy ◽  
Medullary Thyroid ◽  
Hereditary Medullary Thyroid Cancer ◽  
Cancer Syndromes

Hereditary medullary thyroid cancer syndromes comprise familial medullary thyroid cancer (FMTC) and multiple endocrine neoplasia types 2A and 2B. Hereditary medullary thyroid cancers have an autosomal dominant pattern of inheritance and are caused by activating germline point mutations in the RET proto-oncogene. Evaluation of the onset, extent, and progression of hereditary medullary thyroid cancer associated with specific RET mutations has enabled clinicians to treat patients based on the level of risk associated with their specific mutation. Children identified by RET screening to be at risk for the development of medullary thyroid cancer can be treated with prophylactic thyroidectomy before developing the disease. This review covers the diagnosis, evaluation, timing of surgical management, and optimal follow-up of patients with hereditary medullary thyroid cancer syndromes.

CD15 (LeuM1) immunoreactivity: Prognostic factor for sporadic and hereditary medullary thyroid cancer?

1994 ◽  
Vol 18 (4) ◽  
pp. 583-587 ◽  
Author(s):  
Friedrich L�ngle ◽  
Thomas Soliman ◽  
Nikolaus Neuhold ◽  
Gerold Widhalm ◽  
Bruno Niederle ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Prognostic Factor ◽  
Medullary Thyroid Cancer ◽  
Medullary Thyroid ◽  
Hereditary Medullary Thyroid Cancer
Sign in / Sign up

Export Citation Format

Share Document